Allurion Technologies' gastric balloon and Novo Nordisk's semaglutide achieved 20.3% weight loss in a trial. Read more here.

Roth MKM keeps a Buy rating and $16 price target on Allurion Technologies (ALUR) after its initial results from Allurion Program-GLP-1 combo.

Chardan notes that Allurion has announced additional data evaluating the use of its Allurion Balloon in combination with patients be treated ...

Shares of Allurion Technologies on Friday surged a day after the company said it received positive results about the effectiveness of its gastric balloon in combination with a low dose of the ...

Allurion Announces Initial Results on the Combination of the Allurion Program With Low-dose GLP-1 Therapy to Optimize Muscle Mass and GLP-1 Adherence Average Total Weight Loss of 20% With 15% ...

NATICK, Mass. - Allurion Technologies, Inc. (NYSE: ALUR), a medical company focused on obesity treatment currently trading near its 52-week low at $2.27, has announced promising initial results ...

U.S. stock futures declined on Friday after tumbling in trade on Thursday. Futures of all four indices were lower in ...

NATICK, Mass., February 25, 2025--(BUSINESS WIRE)--Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a company dedicated to ending obesity ...

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced ...

ALLURION TECHNOLOGIES ($ALUR) is expected to release its quarterly earnings data on Wednesday, March 19th before market open, per Finnhub. Analysts are expecting ...